ArriVent BioPharma (AVBP) Cash from Operations (2023 - 2026)

ArriVent BioPharma has disclosed Cash from Operations across 4 years of filings, most recently posting 41892000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 41892000.0, up 38.4% year-over-year; the trailing twelve-month figure through Mar 2026 was 134472000.0 (down 12.44% YoY), and the FY2025 annual result was 160588000.0, down 128.72% from the prior year.
• Cash from Operations came in at 41892000.0 for Q1 2026 at ArriVent BioPharma, down from 30658000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 8606000.0 in Q2 2023 to a low of 68008000.0 in Q1 2025.
• The 4-year median for Cash from Operations is 18628000.0 (2024), against an average of 25271846.15.
• Across the five-year window, Cash from Operations tumbled 265.08% in 2025 and soared 38.4% in 2026, its largest moves.
• ArriVent BioPharma's Cash from Operations stood at 14913000.0 in 2023, then dropped by 8.31% to 16152000.0 in 2024, then sank by 89.81% to 30658000.0 in 2025, then tumbled by 36.64% to 41892000.0 in 2026.
• The last three Cash from Operations figures came in at 41892000.0 (Q1 2026), 30658000.0 (Q4 2025), and 35798000.0 (Q3 2025), per Business Quant data.